Evidence map›Paper›PMID 26609459›Full record

ArticleCase reports in rheumatology2015

Efficacy of Adalimumab in a Girl with Refractory Intestinal Behcet's Disease.

Mariko Kaji, Takayuki Kishi, Takako Miyamae, Satoru Nagata, Hisashi Yamanaka, Satoshi Fujikawa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  2. Is Optimal Management of Recurrent Aphthous Stomatitis Possible? A Reality Check.Journal of clinical and diagnostic research : JCDR · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mariko KajiDepartment of Pediatrics, Tokyo Women's Medical University, No. 8-1, Kawadacho, Shinjuku-ku, Tokyo 162-0054, Japan.
Takayuki KishiDepartment of Pediatrics, Tokyo Women's Medical University, No. 8-1, Kawadacho, Shinjuku-ku, Tokyo 162-0054, Japan ; Institute of Rheumatology, Tokyo Women's Medical University, No. 10-22, Kawadacho, Shinjuku-ku, Tokyo 162-0054, Japan.
Takako MiyamaeDepartment of Pediatrics, Tokyo Women's Medical University, No. 8-1, Kawadacho, Shinjuku-ku, Tokyo 162-0054, Japan ; Institute of Rheumatology, Tokyo Women's Medical University, No. 10-22, Kawadacho, Shinjuku-ku, Tokyo 162-0054, Japan.
Satoru NagataDepartment of Pediatrics, Tokyo Women's Medical University, No. 8-1, Kawadacho, Shinjuku-ku, Tokyo 162-0054, Japan.
Hisashi YamanakaInstitute of Rheumatology, Tokyo Women's Medical University, No. 10-22, Kawadacho, Shinjuku-ku, Tokyo 162-0054, Japan.
Satoshi FujikawaFujikawa Pediatrics Clinic, No. 7-29-2, Ooi, Shinagawa-ku, Tokyo 140-0014, Japan.
Tokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe our experience with a juvenile patient who had refractory intestinal Behcet's disease that responded to adalimumab, a fully humanized antibody against soluble TNF-α and its receptor. The patient, a 13-year-old girl, presented with oral aphthous ulcers, vulvar pain, and rashes on the lower extremities. She gradually developed a low-grade fever, abdominal pain, diarrhea, and hematochezia. Lower gastrointestinal endoscopy revealed ulcers in the terminal ileum, consistent with intestinal Behcet's disease. Methylprednisolone pulse therapy was initiated, after which the symptoms transiently improved, but, during the corticosteroid taper, the abdominal pain recurred. The symptoms resolved soon after the administration of adalimumab. Of importance, the dose of corticosteroids was successfully reduced without exacerbation during 8 months of observation. This is the first reported case in which adalimumab was used for pediatric gastrointestinal Behcet's disease. Adalimumab is a good choice for intestinal Behcet's disease refractory to conventional treatment.

Identifiers

PMID26609459
PMCPMC4644826
OpenAlexW2176264578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.